3.C 11
Alternative Names: 3.C-11Latest Information Update: 23 Dec 2025
At a glance
- Originator Nextera
- Class Monoclonal antibodies
- Mechanism of Action Immunosuppressants; T lymphocyte inhibitors
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Coeliac disease
Most Recent Events
- 18 Sep 2025 New profile created on the basis of 9449737; 3909298; created np as lead candidate emerged and mail sent to the company to confirm the development of any additional candidates; searched for the patents but did not find any patent related info
- 07 Jul 2025 Preclinical trials in Coeliac disease in Norway (Parenteral) (Prior to July 2025)
- 07 Jul 2025 Pharmacodynamics data from a preclinical study in Coeliac disease released by Nextera (Prior to July 2025)